Dme Capital Management, LP Roivant Sciences Ltd. Transaction History
Dme Capital Management, LP
- $2.33 Trillion
- Q2 2025
A detailed history of Dme Capital Management, LP transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Dme Capital Management, LP holds 4,551,057 shares of ROIV stock, worth $73 Million. This represents 2.21% of its overall portfolio holdings.
Number of Shares
4,551,057
Previous 5,441,167
16.36%
Holding current value
$73 Million
Previous $54.9 Billion
6.58%
% of portfolio
2.21%
Previous 2.78%
Shares
6 transactions
Others Institutions Holding ROIV
# of Institutions
361Shares Held
456MCall Options Held
8.36MPut Options Held
760K-
Sb Investment Advisers (Uk) LTD London, X060MShares$961 Million5.36% of portfolio
-
Morgan Stanley New York, NY44.7MShares$716 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA39.3MShares$630 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$567 Million0.01% of portfolio
-
Viking Global Investors LP34.2MShares$549 Million1.22% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $11.3B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...